CD274 and acute myeloid leukemia: It remains to be explored in future preclinical studies whether baseline or therapy-induced PD-L1 expression, for instance by ADCC-driven IFN-γ45, affects the activity of cellular immunotherapies in AML, while on the other hand providing opportunities for potential combinations of AFM28 with PD-1 negative NK cell products or PD-1/PD-L1 checkpoint therapy.